Pacira Pharmaceuticals Inc (PCRX)

Currency in USD
36.48
+0.02(+0.05%)
Closed·
Advertisement
Showing Pacira historical data. For real-time data please try another search
Fair Value
Day's Range
36.4836.49
52 wk Range
18.8036.67
Key Statistics
Prev. Close
36.48
Open
36.48
Day's Range
36.48-36.49
52 wk Range
18.8-36.67
Volume
1.81M
Average Volume (3m)
1.32M
1-Year Change
49.5695%
Book Value / Share
17.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PCRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.57
Downside
-7.97%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Pacira Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

0 Buy
9 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 33.57
(-7.97% Downside)

Pacira Pharmaceuticals Inc SWOT Analysis


Patent Peril
Explore Pacira's battle against generic competition as legal challenges threaten its flagship product Exparel, potentially eroding market share and revenues
NOPAIN, Big Gain?
Delve into Pacira's NOPAIN initiative and new partnerships, offering hope for growth amid challenges in the non-opioid pain management market
Outpatient Opportunity
Learn how recent CMS rule changes could boost Pacira's Exparel and iovera adoption in outpatient settings, expanding market reach
Financial Fortitude
Analysts set price targets ranging from $14 to $37, with Pacira's strong margins and cash flow suggesting resilience despite market headwinds
Read full SWOT analysis

Pacira Pharmaceuticals Inc Earnings Call Summary for Q2/2026

  • Q2 revenue reached $192.4M, up 6% YoY, beating consensus by 0.7%; EXPAREL sales rose 3% to $147.8M, ZILRETTA up 4% to $32.6M.
  • Non-GAAP gross margin fell 400bps to 78% due to product mix and manufacturing costs; adjusted EBITDA totaled $48.7M for the quarter.
  • Sold iovera° business to Zimmer Biomet for $70M upfront; management refocusing as pure pharmaceutical company versus pharma/med-tech hybrid.
  • Full-year 2026 revenue guidance lowered to $735-760M from $745-770M to reflect iovera° divestiture; EXPAREL outlook unchanged at $600-620M.
  • Key catalysts include Phase III ZILRETTA shoulder osteoarthritis data, iovera° spasticity study results, and Phase II PCRX-201 readout by year-end.
Last Updated: 04/08/2026, 22:24
Read Full Transcript

Earnings

Latest Release
18/11/2026
EPS / Forecast
0.70 / 0.73
Revenue / Forecast
176.65M / 182.86M
EPS Revisions
Last 90 days

Pacira (PCRX) Income Statement & Profits

Compare PCRX to Peers and Sector

Metrics to compare
PCRX
Peers
Sector
Relationship
P/E Ratio
38.8x11.7x−0.2x
PEG Ratio
0.41−0.370.00
Price/Book
2.1x2.7x2.6x
Price / LTM Sales
2.0x2.8x2.7x
Upside (Analyst Target)
−4.1%56.6%68.5%
Fair Value Upside
Unlock32.1%11.5%Unlock

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Employees
827

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
21.71M54.14%791.83M
Other Institutional Investors
22.03M45.86%803.57M
Public Companies & Retail Investors
0.000.00%0.00
Total
43.73M100.00%1.6B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.16.72%6,705,809244,628
Vanguard Portfolio Management, LLC6.00%2,406,23887,780

People Also Watch

2.560
ALEC
-0.39%
87.69
EXPO
-0.56%
22.00
OSPN
-3.21%
57.88
VCEL
+0.70%
29.04
SUPN
+0.73%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.